AQR Capital Management
ZYNE

AQR Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

AQR Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-27,223
Closed -$104K – 2180
2020
Q1 		$104K Buy
27,223
+2,526
+10% +$11.7K ﹤0.01% 1962
2019
Q4 		$149K Buy
24,697
+10,395
+73% +$71.1K ﹤0.01% 2043
2019
Q3 		$108K Buy
+14,302
New +$161K ﹤0.01% 2073

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management's ZYNE Position: Q2 2020 in Review

AQR Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 27,223 shares — an estimated $104K sold.

AQR Capital Management first reported a position in ZYNE in Q3 2019 and held it in 3 quarters. The position peaked at $149K in Q4 2019. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • AQR Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • AQR Capital Management sold 27,223 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $104K.
  • AQR Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 3 quarters.
  • AQR Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $149K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on AQR Capital Management's 13F filing for Q2 2020, filed 17 Aug 2020.